Chronic kidney disease (CKD) is an urgent and growing global challenge. About 850 million people suffer from kidney disease globally. We estimate that as many as 10 million of them may have progressed to end-stage kidney disease. Our focus is on helping you support greater access to care and better outcomes for patients as they sequence through their therapy journey. While patient population is growing, time and cost resources are not increasing. We understand the need of meaningful innovative medicines that help in delivering better outcomes for patients. Across the continuum of kidney disease care, we are committed to leading access to insight-driven innovative medicines so patients can live their best lives.
